吉西他滨及长春瑞滨联合顺铂对晚期耐药乳腺癌的治疗观察

Clinical observation of gemcitabin and vinorelbine combined with cisplatin in the treatment of advanced breast cancer

目的:观察吉西他滨及长春瑞滨分别联合顺铂的化疗方案治疗对蒽环类和紫杉类耐药的复发转移性晚期乳腺癌的疗效及不良反应。方法:将56例乳腺癌患者随机分为A、B两组各28例,A组应用吉西他滨1000mg/m2进行静脉滴注30min,第1、8天;顺铂25mg/m2静脉滴注,第1～3天。B组应用长春瑞滨25mg/m2静脉滴注,第1、8天;顺铂用法同A组。每21天为1个周期,至少化疗2个周期后评价疗效。结果:A组总有效率为57.1%,B组总有效率为53.6%,两组疗效差异无统计学意义。结论:吉西他滨及长春瑞滨联合顺铂方案治疗对蒽环类和紫杉类耐药的晚期乳腺癌疗效较好,不良反应可以耐受。

Objective：To evaluate the efficacy and adverse effects of gemcitabin and vinorelbine combined with cisplatin in the treatment on patients with anthracycline and taxane resistant advanced breast cancer.Methods：Fifty six patients with advanced breast cancer were divided into two groups randomly.Group A received gemcitabin 1 000 mg/m2 d1,8;and cisplatin 25 mg/m2 d1-3.Group B received vinorelbine 25 mg/m2 d1,8;and cisplatin 25 mg/m2 d1-3.Every 21 days were one cycle and at least 2 cycles were given.Results：The response rate（RR） of gemcitabin regimen was 57.1%.The response rate（RR） of vinorelbine regimen was 53.6%.There was no significant difference between the two groups.Conclusion：Gemcitabin and vinorelbine combined with cisplatin regimens show good efficacy in the treatment on patients with anthracycline and taxane resistant advanced breast cancer.The adverse effects are tolerated.